Claims for Patent: 9,340,538

Summary for Patent: 9,340,538

Title:	Dihydropyrimidine compounds and their application in pharmaceuticals
Abstract:	Provided herein are dihydropyrimidine compounds and their pharmaceutical applications, especially for use in treating and preventing HBV diseases. Specifically, provided herein are compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is the use of the compounds having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof for treating and preventing HBV diseases. ##STR00001##
Inventor(s):	Zhang; Yingjun (Dongguan, CN), Ren; Qingyun (Dongguan, CN), Liu; Xinchang (Dongguan, CN), Goldmann; Siegfried (Wuppertal, DE)
Assignee:	SUNSHINE LAKE PHARMA CO., LTD. (Dongguan, Guangdong, CN)
Application Number:	14/416,061
Patent Claims:	1. A compound of Formula (I) or (Ia) ##STR00267## or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein: each A is a bond, --O--, --S--, or --NR.sup.5--; each R is --X--Z; X is --(CR.sup.7R.sup.7a).sub.m-- or --C(.dbd.O)--; Z has Formula (II) or (IIa): ##STR00268## wherein each B is a bond, --(CR.sup.7R.sup.7a).sub.m-- or --C(.dbd.O)--; each W is CR.sup.7 or N; each Y is --(CR.sup.7R.sup.7a).sub.m-- or --O--; each R.sup.1 is aryl or heteroaryl; each R.sup.2 is H, alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl or alkoxycarbonyl; each R.sup.3 is aryl or heteroaryl; each R.sup.4 is H, or C.sub.1-4 alkyl; R.sup.5 is H, alkyl, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8, alkenyl or alkynyl; each R.sup.7a and R.sup.7 is independently H, F, Cl, Br, alkyl, haloalkyl, --(CH.sub.2).sub.m--OH or --(CH.sub.2).sub.m--C(.dbd.O)O--R.sup.8; each R.sup.8 and R.sup.8a is independently H, alkyl, haloalkyl, aminoalkyl, Boc-NH-alkyl, alkoxy, --(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--C(.dbd.O)O--(CH.sub.2).sub.m--H or --(CH.sub.2).sub.m--OC(.dbd.O)--(CH.sub.2).sub.m--H; Boc is tert-butyloxycarbonyl; each R.sup.9 is independently --(CR.sup.7R.sup.7a).sub.t--OH, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--(CR.sup.7R.sup.7a).sub.m--OC(.dbd- .O)O--R.sup.8, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--(CR.sup.7R.sup.7a).sub.m--OC(.dbd- .O)--R.sup.8, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--(CR.sup.7R.sup.7a).sub.m--C(.dbd.- O)O--R.sup.8, --(CR.sup.7R.sup.7a).sub.t--OC(.dbd.O)--R.sup.8, or --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)N(R.sup.8).sub.2, with the proviso that when R.sup.9 is --(CR.sup.7R.sup.7a).sub.t--OH, R.sup.3 is aryl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl; each n is independently 1, 2 or 3; each t is independently 1, 2, 3 or 4; each m is independently 0, 1, 2, 3 or 4; and optionally each of aryl, heteroaryl, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, alkoxycarbonyl, aralkyl, heteroarylalkyl, aminoalkyl, alkoxy, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl, triazinyl, heterocyclyl and heterocyclylalkyl described above, is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, I, alkyl, alkoxy, cyano, hydroxy, nitro, alkylamino, amino, trifluoromethyl, trifluoromethoxy, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8a, haloalkyl-substituted aryl, halogen-substituted aryl, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)N(R.sup.8a).sub.2 or trifluoromethylsulfonyl. 2. The compound according to claim 1, wherein Z has Formula (III) or (IIIa): ##STR00269## wherein each B is a bond or --(CR.sup.7R.sup.7a).sub.m--; each Y is --(CR.sup.7R.sup.7a).sub.m-- or --O--; each R.sup.7a and R.sup.7 is independently H, F, Cl, Br, C.sub.1-4 alkyl, --(CH.sub.2).sub.m--OH, C.sub.1-4 haloalkyl or --(CH.sub.2).sub.m--C(.dbd.O)O--R.sup.8; each R.sup.8 is independently H, C.sub.1-6 alkyl, C.sub.1-4 haloalkyl, amino-C.sub.1-4-alkyl, Boc-NH--C.sub.1-4-alkyl, C.sub.1-4 alkoxy, --(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--C(.dbd.O)O--(CH.sub.2).sub.m--H or --(CH.sub.2).sub.m--OC(.dbd.O)--(CH.sub.2).sub.m--H; each R.sup.9 is independently --(CR.sup.7R.sup.7a).sub.t--OH, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--(CR.sup.7R.sup.7a).sub.m--OC(.dbd- .O)O--R.sup.8, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--(CR.sup.7R.sup.7a).sub.m--OC(.dbd- .O)--R.sup.8, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--(CR.sup.7R.sup.7a).sub.m--C(.dbd.- O)O--R.sup.8, --(CR.sup.7R.sup.7a).sub.t--OC(.dbd.O)--R.sup.8, or --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)N(R.sup.8).sub.2, with the proviso that when R.sup.9 is --(CR.sup.7R.sup.7a).sub.t--OH, R.sup.3 is C.sub.6-10 aryl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl; each n is independently 1 or 2; each t is independently 1, 2, 3 or 4; and each m is independently 0, 1, 2, 3 or 4. 3. The compound according to claim 2, wherein Z is ##STR00270## wherein each R.sup.7 and R.sup.7a is independently H, methyl, ethyl, --(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--C(.dbd.O)O--R.sup.8 or propyl; each R.sup.8 is independently H, methyl, ethyl, propyl, isopropyl, butyl, 1-methylpropyl, 2-methylpropyl, aminomethyl, 1-amino-2-methylpropyl, 1-aminoethyl, 2-aminoethyl, 1-aminobutyl, 1-aminopropyl, 2-aminopropyl, Boc-NH-methyl, 1-Boc-NH-2-methylpropyl, 1-Boc-NH-ethyl, 2-Boc-NH-ethyl, 1-Boc-NH-butyl, 1-Boc-NH-propyl, 2-Boc-NH-propyl, methoxy, ethoxy, --(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--C(.dbd.O)O--(CH.sub.2).sub.m--H, --(CH.sub.2).sub.m--OC(.dbd.O)--(CH.sub.2).sub.m--H or tert-butyl; and each R.sup.9 is independently --(CR.sup.7R.sup.7a).sub.t--OH, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--(CR.sup.7R.sup.7a).sub.m--OC(.dbd- .O)O--R.sup.8, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--(CR.sup.7R.sup.7a).sub.m--OC(.dbd- .O)--R.sup.8, --(CR.sup.7R.sup.7a).sub.t--OC(.dbd.O)--R.sup.8 or --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)N(R.sup.8).sub.2, with the proviso that when R.sup.9 is --(CR.sup.7R.sup.7a).sub.t--OH, R.sup.3 is phenyl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl. 4. The compound according to claim 1, wherein R.sup.3 is C.sub.6-10 aryl or 5-6 membered heteroaryl, and optionally each of the heteroaryl and aryl is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, methylamino, ethylamino, cyano, hydroxy, nitro, amino, trifluoromethyl, trifluoromethoxy, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8a, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)N(R.sup.8a).sub.2 or trifluoromethylsulfonyl; each R.sup.7a and R.sup.7 is independently H, F, Cl, Br, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, --(CH.sub.2).sub.m--OH or --(CH.sub.2).sub.m--C(.dbd.O)O--R.sup.8; and each R.sup.8a and R.sup.8 is independently H, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, amino-C.sub.1-4-alkyl, Boc-NH--C.sub.1-4-alkyl, C.sub.1-4 alkoxy, --(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--C(.dbd.O)O--(CH.sub.2).sub.m--H or --(CH.sub.2).sub.m--OC(.dbd.O)--(CH.sub.2).sub.m--H. 5. The compound according to claim 4, wherein R.sup.3 has one of the following formulae: ##STR00271## wherein each X.sup.1 is independently 0, S, NR.sup.11 or CR.sup.12R.sup.12a; each X.sup.2, X.sup.3, X.sup.4, X.sup.5 and X.sup.6 is independently N or CR.sup.12; wherein at most three or four of the X.sup.2, X.sup.3, X.sup.4, X.sup.5 and X.sup.6 are N; each R.sup.16 is independently H, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, methylamino, ethylamino, cyano, hydroxy, nitro, amino, trifluoromethyl, trifluoromethoxy, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8a, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)N(R.sup.8a).sub.2 or trifluoromethylsulfonyl; each R.sup.11 is independently H, methyl, ethyl, propyl, isopropyl, butyl, trifluoromethyl, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)N(R.sup.8a).sub.2 or --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8a; each R.sup.12 and R.sup.12a is independently H, F, Cl, Br, I, methyl, ethyl, propyl, isopropyl, butyl, methoxy, ethoxy, methylamino, ethylamino, cyano, hydroxy, nitro, amino, trifluoromethyl, trifluoromethoxy, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8a, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)N(R.sup.8a).sub.2 or trifluoromethylsulfonyl; each R.sup.7a and R.sup.7 is independently H, F, Cl, Br, C.sub.1-4 alkyl, --(CH.sub.2).sub.m--OH, C.sub.1-4 haloalkyl or --(CH.sub.2).sub.m--C(.dbd.O)O--R.sup.8; each R.sup.8a and R.sup.8 is independently H, C.sub.1-4 alkyl, C.sub.1-4 haloalkyl, amino-C.sub.1-4-alkyl, Boc-NH--C.sub.1-4-alkyl, C.sub.1-4 alkoxy, --(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--C(.dbd.O)O--(CH.sub.2).sub.m--H or --(CH.sub.2).sub.m--OC(.dbd.O)--(CH.sub.2).sub.m--H; each m is independently 0, 1, 2, 3 or 4; and each p is independently 0, 1, 2 or 3. 6. The compound according to claim 5, wherein R.sup.3 has one of the following formulae: ##STR00272## wherein each R.sup.10 is independently H, F, Cl, methyl, ethyl, cyano, hydroxy, nitro, amino, methoxy, ethoxy, trifluoromethyl, trifluoromethoxy, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8a, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)N(R.sup.8a).sub.2 or trifluoromethylsulfonyl; each R.sup.11 is independently H, methyl, ethyl, propyl, isopropyl, butyl, trifluoromethyl or --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8a; each R.sup.7a and R.sup.7 is independently H, methyl, ethyl, --(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--C(.dbd.O)O--R.sup.8 or propyl; each R.sup.8 and R.sup.8a is independently H, methyl, ethyl, propyl, isopropyl, butyl, 2-methylpropyl, 1-methylpropyl, aminomethyl, 1-amino-2-methylpropyl, 1-aminoethyl, 2-aminoethyl, 1-aminobutyl, 1-aminopropyl, 2-aminopropyl, Boc-NH-methyl, 1-Boc-NH-2-methylpropyl, 1-Boc-NH-ethyl, 2-Boc-NH-ethyl, 1-Boc-NH-butyl, 1-Boc-NH-propyl, 2-Boc-NH-propyl, methoxy, ethoxy, --(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--C(.dbd.O)O--(CH.sub.2).sub.m--H, --(CH.sub.2).sub.m--OC(.dbd.O)--(CH.sub.2).sub.m--H or tert-butyl; and each p is independently 0, 1, 2 or 3. 7. The compound according to claim 1, wherein R.sup.1 is C.sub.6-10 aryl, and the aryl is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, cyano, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, nitro, 4-(trifluoromethyl)phenyl, 3,5-bis(trifluoromethyl)phenyl or trifluoromethyl; R.sup.2 is H, or C.sub.1-4 alkyl; and R.sup.5 is H, or C.sub.1-4 alkyl. 8. The compound according to claim 7, wherein R.sup.1 is phenyl or a phenyl substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, Br, nitro, 4-(trifluoromethyl)phenyl, 3,5-bis(trifluoromethyl)phenyl or trifluoromethyl. 9. The compound according to claim 1 having Formula (IV) or (IVa), ##STR00273## or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, wherein Z has Formula (II) or (IIa): ##STR00274## wherein each B is a bond or --(CR.sup.7R.sup.7a).sub.m--; each W is CR.sup.7 or N; each Y is --(CR.sup.7R.sup.7a).sub.m-- or --O--; each R.sup.2 is H, or C.sub.1-4 alkyl; each R.sup.3 is C.sub.6-10 aryl or 5-6 membered heteroaryl, and optionally each of the heteroaryl and aryl is independently substituted with one or more substituents which are the same or different, wherein the substituent is H, F, Cl, methyl, ethyl, propyl, cyano, trifluoromethyl, methoxy, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)N(R.sup.8a).sub.2 or --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8a; each R.sup.7a and R.sup.7 is independently H, --(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--C(.dbd.O)O--R.sup.8 or C.sub.1-4 alkyl; each R.sup.8 and R.sup.8a is independently H, amino-C.sub.1-4-alkyl, Boc-NH--C.sub.1-4-alkyl, C.sub.1-4 alkoxy, --(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--C(.dbd.O)O--(CH.sub.2).sub.m--H, --(CH.sub.2).sub.m--OC(.dbd.O)--(CH.sub.2).sub.m--H or C.sub.1-6 alkyl; each R.sup.9 is independently --(CR.sup.7R.sup.7a).sub.t--OH, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--(CR.sup.7R.sup.7a).sub.m--OC(.dbd- .O)O--R.sup.8, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--(CR.sup.7R.sup.7a).sub.m--OC(.dbd- .O)--R.sup.8, --(CR.sup.7R.sup.7a).sub.t--OC(.dbd.O)--R.sup.8 or --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)N(R.sup.8).sub.2, with the proviso that when R.sup.9 is --(CR.sup.7R.sup.7a).sub.t--OH, R.sup.3 is C.sub.6-10 aryl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl; each R.sup.13 is independently H, F, Cl, Br, cyano, nitro, 4-(trifluoromethyl)phenyl, 3,5-bis(trifluoromethyl)phenyl or trifluoromethyl; each n is independently 1 or 2; each t is independently 1, 2, 3 or 4; and each m is independently 0, 1, 2, 3 or 4. 10. The compound according to claim 9, wherein Z has Formula (II) or (IIa): ##STR00275## wherein each B is a bond or --(CR.sup.7R.sup.7a).sub.m--; each W is CR.sup.7 or N; each Y is --(CR.sup.7R.sup.7a).sub.m-- or --O--; each R.sup.7a and R.sup.7 is independently H, methyl, --(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--C(.dbd.O)O--R.sup.8, ethyl or propyl; each R.sup.8 is independently H, methyl, ethyl, propyl, isopropyl, butyl, 1-methylpropyl, 2-methylpropyl, tert-butyl, aminomethyl, 1-amino-2-methylpropyl, 1-aminoethyl, 2-aminoethyl, 1-aminobutyl, 1-aminopropyl, 2-aminopropyl, Boc-NH-methyl, 1-Boc-NH-2-methylpropyl, 1-Boc-NH-ethyl, 2-Boc-NH-ethyl, 1-Boc-NH-butyl, 1-Boc-NH-propyl, 2-Boc-NH-propyl, methoxy, ethoxy, --(CH.sub.2).sub.m--OH, --(CH.sub.2).sub.m--C(.dbd.O)O--(CH.sub.2).sub.m--H or --(CH.sub.2).sub.m--OC(.dbd.O)--(CH.sub.2).sub.m--H; each R.sup.8a is independently H, methyl, ethyl, isopropyl or propyl; each R.sup.9 is independently --(CR.sup.7R.sup.7a).sub.t--OH, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--R.sup.8, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--(CR.sup.7R.sup.7a).sub.m--OC(.dbd- .O)O--R.sup.8, --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)O--(CR.sup.7R.sup.7a).sub.m--OC(.dbd- .O)--R.sup.8, --(CR.sup.7R.sup.7a).sub.t--OC(.dbd.O)--R.sup.8, or --(CR.sup.7R.sup.7a).sub.m--C(.dbd.O)N(R.sup.8).sub.2, with the proviso that when R.sup.9 is --(CR.sup.7R.sup.7a).sub.t--OH, R.sup.3 is phenyl, furyl, imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyrimidinyl, pyridazinyl, thiazolyl, diazolyl, triazolyl, tetrazolyl, thienyl, pyrazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, pyrazinyl, pyranyl or triazinyl; each m is independently 0, 1, 2, 3 or 4; and each t is independently 1, 2, 3 or 4. 11. The compound according to claim 10, wherein Z is: ##STR00276## ##STR00277## ##STR00278## ##STR00279## ##STR00280## 12. The compound according to claim 9, wherein each R.sup.3 is independently: ##STR00281## ##STR00282## 13. The compound according to claim 1 having one of the following structures: ##STR00283## ##STR00284## ##STR00285## ##STR00286## ##STR00287## ##STR00288## ##STR00289## ##STR00290## ##STR00291## ##STR00292## ##STR00293## ##STR00294## ##STR00295## ##STR00296## ##STR00297## ##STR00298## ##STR00299## ##STR00300## ##STR00301## ##STR00302## ##STR00303## ##STR00304## ##STR00305## ##STR00306## ##STR00307## ##STR00308## ##STR00309## ##STR00310## ##STR00311## ##STR00312## ##STR00313## ##STR00314## ##STR00315## ##STR00316## ##STR00317## ##STR00318## ##STR00319## ##STR00320## ##STR00321## ##STR00322## ##STR00323## ##STR00324## ##STR00325## ##STR00326## or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. 14. A pharmaceutical composition comprising the compound according to claim 1; and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant, vehicle or a combination thereof. 15. The pharmaceutical composition according to claim 14 further comprises an anti-HBV agent. 16. The pharmaceutical composition according to claim 15, wherein the anti-HBV agent is a HBV polymerase inhibitor, immunomodulator or interferon. 17. The pharmaceutical composition according to claim 15, wherein the anti-HBV agent is lamivudine, telbivudine, tenofovir, entecavir, adefovir dipivoxil, alfaferone, alloferon, celmoleukin, clevudine, emtricitabine, famciclovir, feron, hepatect CP, intefen, interferon .alpha.-1b, interferon .alpha., interferon .alpha.-2a, interferon .beta.-1a, interferon .alpha.-2, interleukin-2, mivotilate, nitazoxanide, peginterferon alfa-2a, ribavirin, roferon-A, sizofiran, euforavac, veldona, rintatolimod, phosphazid, heplisav, interferon .alpha.-2b, levamisole, or propagermanium. 18. A method for managing, treating or lessening a viral disease or a HBV disease in a patient, comprising administering to the patient with a therapeutically effective amount of the compound according to claim 1. 19. The method according to claim 18, wherein the viral disease or HBV disease is hepatitis B infection or a disease caused by hepatitis B infection. 20. The method according to claim 19, wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma. 21. A method for managing, treating or lessening a viral disease or a HBV disease in a patient, comprising administering to the patient with a therapeutically effective amount of the pharmaceutical composition according to claim 14. 22. The method according to claim 21, wherein the viral disease or HBV disease is hepatitis B infection or a disease caused by hepatitis B infection. 23. The method according to claim 22, wherein the disease caused by hepatitis B infection is cirrhosis or hepatocellular carcinoma.

Details for Patent 9,340,538

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	ROFERON-A	interferon alfa-2a	For Injection	103145	06/04/1986		2039-02-26
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2039-02-26
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003		2039-02-26
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012		2039-02-26
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002		2039-02-26